COVID-19 is a severe acute respiratory syndrome caused by the SARS-CoV-2 virus. People with comorbidities such as Diabetes Mellitus are at higher risk of developing severe illness and even death. COVID-19 is not only dominated by respiratory manifestations but also by coagulation disorders found in severe COVID-19 patients. This is described by the significant increase in D-dimer levels in severe COVID-19 patients, which results in a high risk of mortality. According to the World Health Organization (WHO), 70% of global deaths are caused by non-communicable diseases. Some COVID-19 complications are non-communicable diseases, such as Diabetes Mellitus and coagulopathy. In patients with Type 2 Diabetes Mellitus and COVID-19, there is a significant increase in hypercoagulability compared to non-diabetic patients. Diabetes Mellitus type 2 patients with COVID-19 are also more prone to hypercoagulability and complications compared to non-diabetic patients with COVID-19. Research has shown that the virus can induce the activation of coagulation factors, hypercoagulability, inflammatory response, and the production of cytokines in COVID-19 patients. The increased levels of D-dimer and fibrinogen suggest the occurrence of hypercoagulability. The presence of diabetes mellitus increases the risk and severity of COVID-19 disease and can affect the disfunction of various organs, including the lungs.